CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Clinical trials for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY explained in plain language.
Never miss a new study
Get alerted when new CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY trials appear
Sign up with your email to follow new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Chemo and stem cell transplant shows promise for Hard-to-Treat autoimmune nerve diseases
Disease control OngoingThis study tests whether a strong chemotherapy combination followed by a stem cell transplant can stop the immune system from attacking the brain, spinal cord, and nerves in people with autoimmune neurologic diseases that haven't improved with standard treatments. About 53 adults…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 17, 2026 05:44 UTC
-
Can a cancer drug cure a rare nerve disease? new study aims to find out
Disease control TerminatedThis study tested whether rituximab, a drug that depletes certain immune cells, could help people with chronic inflammatory demyelinating polyneuropathy (CIDP) stop their current medications and achieve long-term remission. The study planned to enroll 48 adults with CIDP across t…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated May 17, 2026 05:36 UTC
-
Own stem cells tried for rare nerve disease
Disease control NO_LONGER_AVAILABLEThis study tests the safety and early effects of using a patient's own stored stem cells to treat chronic inflammatory demyelinating polyneuropathy (CIDP), a rare nerve disorder. Only one patient who has banked their stem cells at the sponsor's facility can join. The treatment in…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Sponsor: Hope Biosciences Research Foundation • Aim: Disease control
Last updated May 17, 2026 05:34 UTC
-
New hope for CIDP patients: Long-Term batoclimab safety trial underway
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called batoclimab for adults with CIDP, a nerve disorder that causes weakness and numbness. About 108 people who completed a previous study will get weekly injections for up to a year. The goal is to see if the drug is safe and t…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug mimics IVIg to tame nerve inflammation
Disease control OngoingThis study tests a new drug called NVG-2089 in 60 adults with CIDP, a chronic nerve condition that causes weakness and numbness. The drug is designed to calm the immune system, similar to IVIg therapy. Researchers will check if it is safe and if it helps improve symptoms over 14 …
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE2 • Sponsor: Nuvig Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New test could predict falls in muscle disease patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to create a simple test to predict fall risk in people with neuromuscular disorders like muscular dystrophy, ALS, and myasthenia gravis. Researchers will measure how well participants perform tasks like standing up from a chair, walking, and balancing. The goal is…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Sponsor: LMU Klinikum • Aim: Knowledge-focused
Last updated May 07, 2026 18:39 UTC